These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 20806351)

  • 1. Adverse effects of imatinib--dissecting heart from the rest.
    Thachil J
    Cancer; 2011 Jan; 117(1):228; author reply 228-9. PubMed ID: 20806351
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect?
    Distler JH; Distler O
    Ann Rheum Dis; 2007 Jun; 66(6):836. PubMed ID: 17513571
    [No Abstract]   [Full Text] [Related]  

  • 3. Another look at imatinib mesylate.
    Schellings MW; Löwenberg B; Pinto YM
    N Engl J Med; 2007 Mar; 356(11):1183; author reply 1183. PubMed ID: 17361003
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
    Khouri S; Kotliroff A; Lishner M; Amital H
    Isr Med Assoc J; 2008 Apr; 10(4):320-1. PubMed ID: 18548994
    [No Abstract]   [Full Text] [Related]  

  • 5. Imatinib-induced anasarca without heart failure: capillary leakage?
    Sendur MA; Aksoy S; Civelek B; Zengin N
    J BUON; 2012; 17(1):188-9. PubMed ID: 22517720
    [No Abstract]   [Full Text] [Related]  

  • 6. Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
    Breccia M; D'Elia GM; D'Andrea M; Latagliata R; Alimena G
    Eur J Haematol; 2005 Jan; 74(1):89-90. PubMed ID: 15613116
    [No Abstract]   [Full Text] [Related]  

  • 7. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Rosti G; Martinelli G; Baccarani M
    Nat Med; 2007 Jan; 13(1):15; author reply 15-6. PubMed ID: 17206121
    [No Abstract]   [Full Text] [Related]  

  • 8. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Atallah E; Kantarjian H; Cortes J
    Nat Med; 2007 Jan; 13(1):14; author reply 15-6. PubMed ID: 17206119
    [No Abstract]   [Full Text] [Related]  

  • 9. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Hatfield A; Owen S; Pilot PR
    Nat Med; 2007 Jan; 13(1):13; author reply 15-6. PubMed ID: 17206118
    [No Abstract]   [Full Text] [Related]  

  • 10. In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
    Gambacorti-Passerini C; Tornaghi L; Franceschino A; Piazza R; Corneo G; Pogliani E
    Nat Med; 2007 Jan; 13(1):13-4; author reply 15-6. PubMed ID: 17206117
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib.
    Hamberg P; de Jong FA; Boonstra JG; van Doorn J; Verweij J; Sleijfer S
    J Clin Oncol; 2006 Jun; 24(18):e30-1. PubMed ID: 16782905
    [No Abstract]   [Full Text] [Related]  

  • 12. Another look at imatinib mesylate.
    Strebhardt K; Ullrich A
    N Engl J Med; 2006 Dec; 355(23):2481-2. PubMed ID: 17151370
    [No Abstract]   [Full Text] [Related]  

  • 13. Imatinib: a designer drug, another cutaneous complication.
    Dickens E; Lewis F; Bienz N
    Clin Exp Dermatol; 2009 Jul; 34(5):603-4. PubMed ID: 19486036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
    Tamura T; Tasaka T; Fujimoto M; Matsuhashi Y; Fukumot T; Mano S; Kuwajima M; Nagai M
    Haematologica; 2004 Sep; 89(9):ECR32. PubMed ID: 15377484
    [No Abstract]   [Full Text] [Related]  

  • 15. Gleevec may be heart toxic.
    Duke Med Health News; 2007 Jan; 13(1):2. PubMed ID: 17299882
    [No Abstract]   [Full Text] [Related]  

  • 16. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma.
    Porta C; Mutti L; Tassi G
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):149-50. PubMed ID: 16636799
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
    Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.